When direct compression is selected for dimethiamin veterinary tablets at label claims of 25 mg or 50 mg, the API is first pre-blended with microcrystalline cellulose complying with Ph. Eur. type 102 at a 1:1 ratio in a bin blender running at 12 rpm for 15 min, then passed through a 500 µm screen. This first pre-blend step reduces agglomerate formation when the primary excipient mass is added. The final blend contains dimethiamin 10.0% w/w, microcrystalline cellulose 30.0% w/w, lactose monohydrate 55.0% w/w, croscarmellose sodium 4.0% w/w, and magnesium stearate 1.0% w/w. Content uniformity testing follows USP <905>, with individually assayed tablets collected from the beginning, middle, and end of the compression run. A batch is considered acceptable only when the acceptance value is ≤15.0 and the relative standard deviation remains below 5.0%. On a 16-station rotary tablet press equipped with 8 mm biconcave B-tooling, turret speed is maintained at 25–30 rpm, pre-compression force at 2.0–3.5 kN, and main compression force at 8.0–14.0 kN. Lower main compression force produces tablets with friability above 1.0% when tested according to Ph. Eur. 2.9.7, while higher forces are associated with edge chipping on shallow concave punches. Punch filming is a recurring failure mode when residual moisture in the final blend is above 2.5%; polishing the debossed tooling or replacing it with plain punches reduces but does not eliminate the defect. Disintegration time is controlled below 15 min using the Ph. Eur. 2.9.1 method in water at 37 ± 1 °C. Published data for dimethiamin-specific direct compression at this exact particle-size range is limited, so the process window is qualified against nitroimidazole-class powders processed on the same equipment.

What Limits Sterile Filtration Throughput in Dimethiamin Injection Manufacturing?

The limiting factor is usually the combination of holding temperature, pH control, and prefiltration integrity rather than the nominal pore size of the final membrane. Bulk aqueous dimethiamin injection solution is compounded in a jacketed stainless-steel vessel at 20–25 °C, with the API added after a nitrogen sparge to reduce oxidative degradation. The formulation uses 0.9% w/v sodium chloride as tonicity agent and hydrochloric acid or sodium hydroxide for pH adjustment to 3.8–4.5; this window is selected to maintain protonated solubility and minimize free-base precipitation. Before sterile filtration, the solution is passed through a 0.45 µm polyethersulfone prefilter and a 0.22 µm sterilizing-grade composite filter. Throughput is defined by a pressure differential limit of 1.0 bar; the batch is rejected if flow per 0.1 m² of membrane falls below 15 L/h at 20 °C. Viscosity values measured by a falling-ball viscometer at 25 °C are typically below 1.5 mPa·s, so viscosity does not explain rate limitation. The more common rate-limiting factor is the presence of amorphous API fines that block the prefilter when the API is micronized without jet-milling classification. Production-scale equipment behavior shows that installation of a 0.2 m² capsule prefilter upstream of the final 0.22 µm cartridge reduces the number of filter change-outs from 5 to 2 per 200 L batch. Sterile filling into 100 mL type II glass vials is performed under unidirectional airflow with a peristaltic pump; the fill volume is 101.5–103.0 mL to allow for needle withdrawal. Terminal sterilization is avoided when the API exhibits heat sensitivity; therefore the process is validated by Ph. Eur. 2.6.1 sterility testing and by bacterial endotoxin measurement according to USP <85>. Endotoxin limits for veterinary parenteral products are calculated from the maximum administered dose and are often capped at 0.5 EU/mg of API, but the approved label claim must govern. Residual solvent control follows VICH GL18 and ICH Q3C for class 2 and class 3 solvents used during purification.

On poultry and swine production sites where drinking-water medication is the only practical route during acute protozoal outbreaks, dimethiamin is formulated as a water-soluble powder using spray-dried lactose, anhydrous citric acid, sodium bicarbonate, and the API at a 4:1 carrier-to-active ratio. The powder is passed through a 500 µm conical screen and packaged into aluminium-laminated pouches under nitrogen. Dissolution performance is tested by adding 10 g of powder to 1 L of dechlorinated water at 25 ± 1 °C with stirring at 100 rpm; full clarity must be reached within 5 min. The pH of the reconstituted solution is maintained between 5.5 and 6.5 to avoid precipitation of the API in hard water containing calcium and magnesium carbonates. In a 1:100 proportioner set at a stock solution withdrawal rate of 10 L per 1000 L of drinking water, a 5% w/w active powder produces a line concentration of 500 mg/L before accounting for water-consumption variability. Nipple drinker clogging becomes a production problem when undissolved particles exceed 75 µm; sieving through a 150 µm screen and controlling residual moisture below 1.0% reduce blockages. Mixing time in a 500 L ribbon blender is 20–25 min at 20 rpm, with a coefficient of variation of active content below 5.0% after sampling at 10 points following ISO 6497:2002. Pre-drying of the API and carrier at 45 °C for 4 h is required when ambient relative humidity exceeds 60%. Hygroscopic carriers such as sorbitol are avoided because caking above 60% RH causes powder segregation and dosing errors at the proportioner.

Premix Carrier Adsorption and Segregation Control in Bulk Feed

Premix carrier selection for dimethiamin in medicated feed is governed by particle-size overlap, oil adsorption capacity, and electrostatic charge. Corn cob meal with a particle-size range of 300–800 µm is used for low-density premixes, while calcium carbonate carriers with 50–150 µm particles are used for high-density mineral premixes. The API is pre-dispersed in a paddle mixer at a dilution ratio of 1:9 with colloidal silicon dioxide before being layered onto the carrier. Batch-to-batch variation in drug recovery from premix samples taken at the mixer discharge is controlled by the use of a twin-shaft paddle mixer with a fill level of 60–70% and a mixing time of 15 min at 25 rpm. When a 20 kg dimethiamin premix batch is produced at 10% w/w active content, the carrier and API are sampled at 10 discrete points using ISO 6497:2002; acceptance is based on a relative standard deviation below 5.0% and a mean assay within 95–105% of label claim. Segregation during pneumatic conveying is a critical failure mode when the API particle size is below 20 µm and the carrier particle size is above 1000 µm; the fines migrate to the bin walls, producing scale-up assays as low as 70% in the first discharge fraction. To limit this, the premix is further diluted to 1–2% w/w active content before incorporation into a complete feed at a final concentration of 100–200 mg/kg, depending on species-specific registration. The mixing process is validated according to ISO 6497:2002 sampling plans, with the premix incorporated into a horizontal ribbon feed mixer at a ratio of 10 kg per tonne of feed. Dust control is addressed by adding 0.5% w/w food-grade mineral oil to the premix, but this is only permitted where regional feed regulations allow oil addition to dry premixes; mineral oil above 1.0% w/w reduces flowability below the required mass-flow hopper discharge angle of 60°. Commercial feed-mill experience shows that a drop in ambient temperature below 10 °C increases electrostatic adhesion of the API to stainless-steel surfaces, causing assay loss in the first 5% of the batch.

Fluid Bed Granulation Produces Friability-Resistant Oral Granules

Fluid bed granulation of dimethiamin oral granules uses a top-spray configuration with a 30 L bowl, a 1.2 mm two-fluid nozzle, and inlet air temperature of 55–65 °C. The binder solution is hypromellose 3 mPa·s at 5% w/w in purified water, sprayed at 20 g/min; the API is suspended in the binder solution after being pre-sieved through a 150 µm screen. The granulation end point is determined by a product temperature of 36–38 °C and a steady-state pressure drop across the filter bags of 1200–1500 Pa, not by fixed time alone. Granules are dried to a loss on drying of 1.5–2.5% and passed through a 1.0 mm oscillating granulator. The final granules are filled into 10 g sachets. Particle-size acceptance requires >90% of the mass between 250 µm and 1000 µm; a fines fraction below 250 µm above 15% produces rapid dissolution but poor sachet uniformity, while coarse fractions above 1000 µm retard dispersion in water. Equipment behavior shows that filter-bag blinding occurs when the spray rate exceeds 25 g/min at atomizing air pressure below 1.5 bar. The process is monitored by Ph. Eur. 2.9.12 sieve analysis and by loss-on-drying with USP <731>. Incompatibility with primary amine-based binders is controlled by avoiding tromethamine in the binder solution; such amines cause pH drift and increase the risk of API degradation during the drying phase. Published data for dimethiamin-specific granulation kinetics is limited; the process window is qualified by analogy with nitroimidazole-class granulations on the same top-spray equipment.

Where companion animal veterinary clinics require discrete oral dosing, dimethiamin is filled into hard gelatin capsules using a tamping-pin capsule filling machine. The API is pre-blended at 8.0% w/w with lactose monohydrate and pregelatinized starch, then lubricated with 0.5% w/w magnesium stearate. A size 3 capsule shell is filled to a target weight of 180 mg, giving an active content of 14.4 mg per capsule. Fill weight is controlled by automatic checkweighing at the discharge chute; rejection criteria are set at ±5% of target weight. Content uniformity follows USP <905>, with 10 capsules sampled from the start, middle, and end of the filling run. Capsule lock-ring deformation is a recurring production problem when the powder blend has a tapped density below 0.55 g/mL; pre-compression on the tamping pins is adjusted to 12–16 N to increase plug density without fracturing the shell. On a 40,000 capsule/h automatic capsule filler, the dosing disk is machined to a powder bed depth of 14 mm to reduce weight variation. Dissolution testing is performed according to USP <711>, with at least 75% of the label claim released within 30 min in 0.1 N hydrochloric acid at 37 ± 0.5 °C. Capsule filling is performed at 40–50% RH; above 60% RH, the gelatin shells soften and lead to telescoping defects at the closure station.

When Oral Drench Solutions Require Cosolvent and Antimicrobial Preservation

For oral drench solutions administered to cattle and sheep, dimethiamin is dissolved in a cosolvent system composed of propylene glycol 40% v/v, glycerol 10% v/v, and purified water 50% v/v. The API is added at 10–20 mg/mL depending on the approved label claim, and the pH is adjusted to 4.0–5.0 with citric acid. Sodium methyl parahydroxybenzoate 0.18% w/v and sodium propyl parahydroxybenzoate 0.02% w/v serve as antimicrobial preservatives because oral drench containers are multi-dose and may be stored at farm ambient temperature for several days. The solution is mixed in a 250 L stainless-steel tank with a high-shear disperser at 1500 rpm for 30 min, then filtered through a 10 µm polypropylene bag filter. Density and refractive index are checked at 20 °C to confirm batch uniformity; density is held at 1.03–1.05 g/mL. A dosing gun or draw-off tube must not introduce air bubbles above 0.1% v/v because air entrapment causes volume error in field dosing. The process is challenged by low-temperature storage at 4 °C for 7 days; any visible precipitation triggers reformulation with reduced API concentration or increased propylene glycol. Equipment cleaning between batches uses purified water at 60 °C followed by 0.1 N sodium hydroxide, because residual organic films on tank walls promote microbial growth in multi-dose containers. Preservative efficacy is evaluated according to Ph. Eur. 5.1.3, with log reduction criteria for bacteria and fungi met at 7 and 14 days. In use, the oral drench should not be combined with primary amine-based buffers or strong oxidizing agents because these alter the pH and may compromise API stability.